|
|
|
Home >
Anti-aging Research > Chemotherapy >
Gleevec (imatinib)
Gleevec (imatinib)
Related Topics:
News & Research:
-
Korean
Red Ginseng Extract Enhances the Anticancer Effects of Imatinib Mesylate
Through Abrogation p38 and STAT5 Activation in KBM-5 Cells - Phytother
Res. 2015 Apr 8 - "Although imatinib mesylate (IM)
in the treatment of chronic myelogenous leukemia (CML) remains the best
example of successful targeted therapy, majority of patients with CML suffer
its toxicity profile and develop chemoresistance to existing therapeutic
agents ... Korean red ginseng extract broadly suppressed the proliferation
of five different cell lines, but KRGE was found to be the most potent
inducer of apoptosis against KBM-5 cells ... The combination treatment of
KRGE and IM caused pronounced suppression of p38 and signal transducer and
activator of transcription 5 phosphorylation and induced phosphorylation of
p53 compared with the individual treatment. Our results demonstrate that
KRGE can enhance the anticancer activity of IM and may have a substantial
potential in the treatment of CML" - See
ginseng at Amazon.com
 .
-
Predicting Patient Response To Gleevec In Gastrointestinal Stromal Tumors
- Science Daily, 4/21/09
-
Gleevec, The Targeted Cancer Pill, Delivers More Good News To Patients -
Science Daily, 1/2/08
-
Heart Failure Is Rare Among Leukemia Patients on Imatinib - Doctor's
Guide, 9/6/07
-
Factors That Accelerate Resistance to Gleevec Targeted Therapy in
Lymphoblastic Leukemia - Doctor's Guide, 8/30/07
-
'Wrapping' Gleevec Fights Drug-resistant Cancer, Study Shows - Science
Daily, 5/1/07
-
Gleevec Decreases Recurrence for Patients With Primary Gastrointestinal
Stromal Tumor - Doctor's Guide, 4/13/07
-
Imatinib Mesylate Demonstrates Highest Five-Year Overall Survival Rate in
History of Treatment for Patients With Chronic Myeloid Leukemia -
Doctor's Guide, 12/7/06
-
5 Years Later,
Gleevec Fights Cancer - WebMD, 12/6/06
-
Gleevec(R) (Imatinib Mesylate) Approved in US for Five Rare Life-Threatening
Disorders With Limited Treatment Options - Doctor's Guide, 10/20/06
-
New
Drug Target Might Sidestep Gleevec Resistance - Science Daily, 9/22/06
-
Cancer Drug Can be Toxic to the Heart - Doctor's Guide, 7/24/06
-
Imatinib Sets New Treatment Standard in Chronic Myeloid Leukemia With High
Overall Survival, Increasing Response and Decreasing Progression -
Doctor's Guide, 6/15/06
-
Drug
Attacks Prostate Cancer In Mouse Model By Destroying Its Blood Supply -
Science Daily, 6/7/06
-
Patients on Gleevec Continue to Improve With Long-Term Treatment -
Doctor's Guide, 6/5/06
-
Cancer Drug Gleevec Can Interfere With Bone Growth - Intelihealth,
5/10/06
-
Broken Stress Response System Can Contribute to Gleevec Resistance -
Doctor's Guide, 4/20/06
-
Imatinib Alone Not a Long-Term Cure for Chronic Myeloid Leukemia -
Doctor's Guide, 12/15/05
-
Imatinib Therapy Shows Positive Results After 4 Years in Chronic Myeloid
Leukemia - Doctor's Guide, 12/14/05
-
First Report Of Cancer Drug Gleevec As New Target Therapy For Pulmonary
Hypertension - Doctor's Guide, 9/30/05
-
New Drug Shows Promise in Fighting Gleevec-Resistant Chronic Myeloid
Leukemia - Doctor's Guide, 4/21/05
-
Gleevec New CML Gold Standard - WebMD, 4/8/05
-
Imatinib Mesylate (Gleevec) Shows Activity, But Fails to Induce Response in
Recurrent Ovarian Cancer - Doctor's Guide, 3/22/05
-
Compound Fights Gleevec-Resistant Leukemia - HealthDay, 2/14/05
- St. John's Wort -
Imatinib Drug Interactions - Medscape, 12/17/04 - "Coadministration of
imatinib with St. John's wort may compromise imatinib's clinical efficacy"
-
Gleevec a Cost-Effective Treatment - HealthDay, 12/20/04
- Imatinib and Beyond
-- New Developments in the Treatment of CML: An Interview With Brian Druker,
MD - Medscape, 12/20/04
-
Novel Drug Helps Solve Imatinib Resistance in Patients With Leukemia -
Doctor's Guide, 12/6/04
-
New Treatment for Imatinib-Resistant Leukemia - Doctor's Guide, 12/6/04
-
Imatinib Shows Prolonged Efficacy in Early Phase Chronic Myeloid Leukemia
- Doctor's Guide, 12/6/04
-
Higher Doses of Imatinib Lead to Stronger Cytogenetic Responses -
Doctor's Guide, 12/6/04
-
Continuous Imatinib Therapy for 4 Years Improves Chronic Myeloid Leukemia
Survival - Doctor's Guide, 12/6/04
-
Gleevac (Imatinib Mesylate) Appears to Provide Prolonged Efficacy with
Approved 400 mg Daily Dose - Doctor's Guide, 12/6/04
-
Leukemia Drug Gleevec Continues to Amaze - HealthDay, 12/3/04
- St. John's
Wort Thwarts Cancer Drug - WebMD, 10/26/04
-
Leukemia 2004: Imatinib-based Therapy Results in Sustained Remission But
Rarely Cures Chronic Myelogenous Leukemia - Doctor's Guide, 10/14/04
- High-Dose Imatinib
Improves Survival in Gastrointestinal Stromal Tumors - Medscape, 9/24/04
-
New Drug [BMS-354825] Battles Gleevec Resistance - HealthDay, 7/15/04
-
BCR-ABL Positive Leukaemias Show Increasing Resistance to Imatinib Therapy
- Doctor's Guide, 6/15/04
-
St. John's Wort Affects Ca Drug's Metabolism - Clinical Psychiatry News,
6/04
-
Encouraging Early Clinical Results With Imatinib Therapy For Selected
Myeloproliferative Disorders - Doctor's Guide, 5/25/04
-
Imatinib-Induced Complete Cytogenetic Remission of Chronic Myeloid Leukaemia
May Lead to Relapse and Disease Progression: a Case Study - Doctor's
Guide, 4/27/04
-
Imatinib Mesylate Effective for Treatment of Chronic Myeloid Leukaemia but
Interferon-Alpha and Allogeneic Transplant Still Have Key Roles -
Doctor's Guide, 4/22/04
-
Higher Doses Of Imatinib Appear Effective, Safe Treatment for Chronic
Myelogenous Leukemia - Doctor's Guide, 4/13/04
- St. John's Wort
Depletes Cancer-Fighting Drug - WebMD, 3/26/04 -
"when St. John's wort is taken in combination with
Gleevec, it caused the amount of Gleevec in the blood to drop by 30%"
-
Imatinib Highlights Gastrointestinal Stromal Tumors Task Force Report -
Doctor's Guide, 3/12/04
-
Imatinib and Bone Marrow Transplant Are Top Choices for Chronic Myelogenous
Leukemia Treatment - Doctor's Guide, 3/12/04
-
Imatinib Mesylate May Be Effective in Treating Advanced Gastrointestinal
Stromal Tumours - Doctor's Guide, 2/4/04
-
Imatinib Mesylate Reverses Bone Marrow Angiogenesis in Chronic Myeloid
Leukaemia - Doctor's Guide, 1/29/04
-
Imatinib Gives Sustained Response in Gastrointestinal Stromal Cancer -
Doctor's Guide, 1/23/04
-
Higher Doses of Imatinib Mesylate Safely Improve Cytogenetic and Molecular
Response in Chronic Myeloid Leukemia - Doctor's Guide, 1/15/04
-
Six Months of Imatinib May Be Needed to See Response in Patients With
Chronic Myeloid Leukemia - Doctor's Guide, 12/18/03
-
New Data Show Higher Dosing of Gleevec (Imatinib Mesylate) Achieved Higher
Response Rates in Patients with Newly Diagnosed Chronic Myeloid Leukemia
- Doctor's Guide, 12/15/03
-
Gleevec Formally OK'd for Rare Cancer - HealthDay, 12/9/03
-
Gleevec Needs Time to Work - HealthDay, 12/8/03
-
Test Shows Who'll Respond to Gleevec - HealthDay, 12/3/03
-
Simultaneous Imatinib/Simvastatin Administration Increases the Levels of
Simvastatin in Patients with Chronic Myeloid Leukaemia - Doctor's Guide,
11/24/03
-
Imatinib is Effective Therapy for Chronic Myeloid Leukaemia in Patients
Resistant or Intolerant to Interferon Therapy - Doctor's Guide, 11/7/03
-
Imatinib Provides Superior Molecular Response Over Interferon Alfa Plus
Cytarabine in Newly Diagnosed Chronic Myeloid Leukaemia in Chronic Phase
- Doctor's Guide, 10/21/03
-
Imatinib Therapy Substantially Reduced Leukemic Load in Patients with
Chronic Myeloid Leukemia - Doctor's Guide, 10/10/03
- Imatinib Affects Key
Molecular Abnormality in Chronic Myeloid Leukemia - Medscape, 10/8/03
-
Potential Efficacy Of Imatinib Mesylate For Rheumatoid Arthritis -
Doctor's Guide, 9/30/03
- Gleevec May
Fight Alzheimer's Disease - WebMD, 9/29/03
-
Gleevec May Fight Alzheimer's, Too - HealthDay, 9/29/03
-
'Amazing' Leukemia Drug Rescues a Life - HealthDay, 9/26/03
-
Imatinib Combination Regimens May Improve Prognosis in Patients With Chronic
Myelogenous Leukaemia - Doctor's Guide, 9/19/03
-
Imatinib Mesylate Active Against Gastrointestinal Stroma Tumours -
Doctor's Guide, 9/19/03
-
Hypopigmentation A Potential Adverse Effect Of Imatinib Mesylate -
Doctor's Guide, 9/4/03
-
Imatinib Mesylate (STI571) Successfully Treats Extramedullary Blast Crisis
Of Chronic Myelogenous Leukaemia - Doctor's Guide, 8/29/03
-
Imatinib Effective In Treatment Of Malignant Gastrointestinal Stromal
Tumours - Doctor's Guide, 8/12/03
-
Elevated Pretreatment Levels of Plasma Alpha-1 Acid Glycoprotein Linked to
Poor Outcome of Imatinib Therapy in Chronic Myeloid Leukaemia Patients -
Doctor's Guide, 8/8/03
-
Novel Agent Controls Gastrointestinal Stromal Tumors in Patients
Unresponsive to Imatinib (Gleevec) - Doctor's Guide, 7/16/03
-
Lab Tests May Reveal Which Patients with Gastrointestinal Stromal Tumours
Respond to Imatinib - Doctor's Guide, 6/5/03
-
Cancer Drug [Gleevec] Approved for Childhood Leukemia - HealthDay,
5/20/03
- Gleevec New CML
Gold Standard - WebMD, 3/12/03
-
Gleevec New Gold Standard for Chronic Myeloid Leukemia - HealthDay,
3/12/03
-
FDA Approves Gleevac (Imatinib Mesylate) For Treatment Of Chronic Myeloid
Leukemia - Doctor's Guide, 12/23/02
- Gleevec Combined with
Interferon, Cytabarine for CML - Medscape, 12/13/02
- New Mutations Found
in CML Patients Treated with Gleevec - Medscape, 12/12/02
-
Gleevec (Imatinib) Results in Better Molecular Response than Interferon Plus
Cytarabine Arabinoside in Patients with Chronic Myelogenous Leukemia -
Doctor's Guide, 12/13/02
-
Trial Continues to Support Imatinib as Front-line Therapy for Chronic
Myeloid Leukemia - Doctor's Guide, 12/9/02
-
FDA Grants Priority Review for Gleevec(TM) (Imatinib Mesylate) Marketing
Application for First-Line Use in Early Chronic Myeloid Leukemia (CML) -
Doctor's Guide, 8/22/02
-
Imatinib Achieves Durable Results in GIST Patients, but One in Five Develops
Resistance - Doctor's Guide, 5/20/02
-
Gleevec approved for rare stomach cancer - CNN, 2/1/02
- FDA Approves Glivec
(Imatinib) for Certain Gastrointestinal Stromal Tumors - Doctor's Guide,
2/1/02
- Early Positive Gleevec
(Imatinib Mesylate) Data in Newly Diagnosed Chronic Myeloid Leukemia Study
Prompt Protocol Changes - Doctor's Guide, 1/7/02
- Molecularly
Targeted Gleevec Is First Real Glimpse of a Cure - WebMD, 12/26/01
- Imatinib Mesylate Plus
Interferon Proves Safe, Feasible in Chronic Phase Chronic Myeloid Leukaemia
- Doctor's Guide, 12/12/01
- Glivec (Imatinib Mesylate)
May Be New standard of Care for Philadelphia Chromosome-Positive Chronic
Myeloid Leukaemia - Doctor's Guide, 12/10/01
- Clinicians Consider Glivec
(Imatinib Mesylate) Management, Dosing and Response - Doctor's Guide,
12/10/01
- Hematologic, Cytogenic and
Molecular Responses Seen to Gleevec (Imatinib Mesilate) in Patients with Ph+
Chronic Myeloid Leukemia - Doctor's Guide, 12/9/01
- Gleevec (Imatinib
Mesylate) Achieves Hematologic Response in Patients with Accelerated or
Blastic Phase Chronic myeloid Leukemia - Doctor's Guide, 12/9/01
- Major, Durable Responses
to STI571 Seen in Chronic Phase Chronic Myeloid Leukemia - Doctor's
Guide, 12/9/01
- Gleevec Data On Patients
with CML Promising - Doctor's Guide, 12/9/01
Related Searches:
70524
|
|
